{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:40:26Z","timestamp":1787312426660,"version":"build-2736575974"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1093\/ibd\/izy217","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T19:44:55Z","timestamp":1529351095000},"page":"150-155","source":"Crossref","is-referenced-by-count":77,"title":["Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn\u2019s Disease in Children"],"prefix":"10.1093","volume":"25","author":[{"given":"Wael","family":"El-Matary","sequence":"first","affiliation":[{"name":"Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D","family":"Walters","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien Q","family":"Huynh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"deBruyn","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Department of Pediatrics, Faculty of Medicine, University of Calgary, Alberta Children\u2019s Hospital, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Mack","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Eastern Ontario IBD Centre, Department of Pediatrics, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, B.C. Children\u2019s Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E","family":"Sherlock","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Nutrition, McMaster Children\u2019s Hospital, Hamilton Health Sciences, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Church","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Wine","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W","family":"Carroll","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric I","family":"Benchimol","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Eastern Ontario IBD Centre, Department of Pediatrics, University of Ottawa, Ottawa, ON, Canada"},{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, B.C. Children\u2019s Hospital, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"key":"key\n\t\t\t\t2018121208435398700_CIT0001","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MPG.0b013e3182a025ee","article-title":"Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement","volume":"57","author":"de Zoeten","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0002","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ibd.20767","article-title":"Course and treatment of perianal disease in children newly diagnosed with Crohn\u2019s disease","volume":"15","author":"Keljo","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0003","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0022-3468(91)90694-O","article-title":"Perianal complications of pediatric Crohn\u2019s disease","volume":"26","author":"Palder","year":"1991","journal-title":"J Pediatr Surg"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0004","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/ajg.2011.437","article-title":"Clinical and genetic risk factors for perianal Crohn\u2019s disease in a population-based cohort","volume":"107","author":"Eglinton","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0005","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0006","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/MIB.0000000000001171","article-title":"The characteristics and long-term outcomes of pediatric Crohn\u2019s disease patients with perianal disease","volume":"23","author":"Herman","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0007","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.gtc.2012.01.009","article-title":"The evaluation and treatment of Crohn perianal fistulae: EUA, EUS, MRI, and other imaging modalities","volume":"41","author":"Wise","year":"2012","journal-title":"Gastroenterol Clin North Am"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0008","doi-asserted-by":"crossref","first-page":"e6705","DOI":"10.1136\/bmj.e6705","article-title":"Management of anal fistula","volume":"345","author":"Simpson","year":"2012","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MPG.0b013e3181a70f21","article-title":"Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH","volume":"49","author":"Crandall","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ibd.20788","article-title":"Efficacy of infliximab in pediatric Crohn\u2019s disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy","volume":"15","author":"Ruemmele","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0011","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/apt.12928","article-title":"Predictors of response to infliximab in paediatric perianal Crohn\u2019s disease","volume":"40","author":"Dupont-Lucas","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0012","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.1999.00026.x","article-title":"Review article: the efficacy of infliximab in Crohn\u2019s disease\u2013healing of fistulae","volume":"13","author":"Present","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0013","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0014","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0015","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/apt.13970","article-title":"Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn\u2019s disease","volume":"45","author":"Yarur","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0016","first-page":"549","article-title":"Association of induction infliximab levels with clinical response in perianal Crohn\u2019s disease","volume":"11","author":"Davidov","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0017","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1097\/MIB.0000000000001231","article-title":"Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window","volume":"23","author":"Papamichael","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0018","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0019","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0020","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0021","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2012.05057.x","article-title":"Systematic review: antibodies and anti-TNF-\u03b1 levels in inflammatory bowel disease","volume":"35","author":"Chaparro","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0022","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.13754","article-title":"Prognostic factors for long-term infliximab treatment in Crohn\u2019s disease patients: a 20-year single centre experience","volume":"44","author":"Billiet","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0023","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/apa.14008","article-title":"Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease","volume":"106","author":"Deora","year":"2017","journal-title":"Acta Paediatr"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0024","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1097\/MIB.0000000000000420","article-title":"The role of therapeutic drug monitoring of anti-tumor necrosis factor alpha agents in children and adolescents with inflammatory bowel disease","volume":"21","author":"Joosse","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0025","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0026","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn\u2019s disease","volume":"64","author":"Vande Casteele","year":"2015","journal-title":"Gut"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0027","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/gutjnl-2014-308099","article-title":"The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study","volume":"65","author":"Yarur","year":"2016","journal-title":"Gut"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0028","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/apt.12928","article-title":"Predictors of response to infliximab in paediatric perianal Crohn\u2019s disease","volume":"40","author":"Dupont-Lucas","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2018121208435398700_CIT0029","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.cgh.2012.12.042","article-title":"Long-term outcome of perianal fistulizing Crohn\u2019s disease treated with infliximab","volume":"11","author":"Bouguen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/25\/1\/150\/27096695\/izy217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T11:17:36Z","timestamp":1720351056000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/25\/1\/150\/5038315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,6,15]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy217","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733467492.793562762","asserted-by":"object"}]},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,6,15]]}}}